Clinical trial · Interventional
Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
A Randomised Study of High Dose Chemotherapy/Radiotherapy and Autologous Bone Marrow Transplantation in Patients With High Grade Malignant Non-Hodgkin's Lymphoma (Kiel Classification) According to Prognostic Groups
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Bone marrow transplantation may allow doctors to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to study the effectiveness of chemotherapy and radiation therapy plus bone marrow transplantation in treating patients who have aggressive non-Hodgkin's lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (11)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| autologous bone marrow transplantation | Procedure | — | UNRESOLVED |
| bleomycin sulfate | Biological | Bleomycin | ALIAS |
| carmustine | Drug | Carmustine | ALIAS |
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| cytarabine | Drug | Cytarabine | ALIAS |
| doxorubicin hydrochloride | Drug | Doxorubicin | ALIAS |
| etoposide | Drug | Etoposide | ALIAS |
| melphalan | Drug | Melphalan | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 65 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically confirmed aggressive non-Hodgkin's lymphoma requiring chemotherapy
* Stage II, III, or IV
* B cell:
* Centroblastic
* Immunoblastic
* Large cell anaplastic
* Non-Burkitt lymphoblastic
* T cell:
* Pleomorphic medium cell
* Pleomorphic large cell
* Immunoblastic
* Large cell anaplastic
* Lymphoblastic
* No Burkitt (L3) subtype
* No large mediastinal mass OR
* Stage I, II, III, or IV
* Bulk disease greater than 10 cm
* Nodal or extranodal site
* No primary localized gut lymphoma
* No CNS involvement
PATIENT CHARACTERISTICS:
Age:
* 15 to 65
Performance status:
* Not specified
Life expectancy:
* Not specified
Hematopoietic:
* No concurrent bone marrow dysplastic syndromes
Hepatic:
* Bilirubin no greater than 2.5 times upper limit of normal (ULN)
Renal:
* Creatinine no greater than 2.5 times ULN
Other:
* No other malignancy except skin cancer or stage I cervical cancer
* Not pregnant
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* See Disease Characteristics
* No prior chemotherapy
Endocrine therapy:
* Not specified
Radiotherapy:
* Not specified
Surgery:
* Not specifiedReferences
Publications (0)
Data not yet available